Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in <scp>IgA</scp> nephropathy, an update of current clinical trials-Reference-Cited by-同舟云学术

Low dose glucocorticoids, mycophenolate mofetil and hydroxychloroquine in IgA nephropathy, an update of current clinical trials

Published:2024-07-18 Issue: Volume: Page:
ISSN:1320-5358
Container-title:Nephrology
language:en
Short-container-title:Nephrology

Author:

Chen Pei¹²³⁴^ORCID,Lv Jicheng¹²³⁴

Affiliation:

1. Renal Division, Department of Medicine Peking University First Hospital Beijing China

2. Institute of Nephrology Peking University Beijing China

3. Key Laboratory of Renal Disease Ministry of Health of China Beijing China

4. Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University) Ministry of Education Beijing China

Abstract

AbstractThis mini‐review explores glucocorticoids, mycophenolate mofetil (MMF), and hydroxychloroquine (HCQ) in IgA nephropathy (IgAN). It discusses conflicting findings from pivotal trials like TESTING and STOP‐IgAN regarding glucocorticoid efficacy, emphasizing reduced‐dose protocols as potentially safer options. MMF's effectiveness varies among populations, demonstrating promise in Chinese cohorts but yielding inconclusive results elsewhere. HCQ shows potential in reducing proteinuria, with ongoing trials investigating its long‐term benefits.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/nep.14369

Reference17 articles.

1. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy

2. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy

3. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy

4. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial

5. Corticosteroids in IgA Nephropathy: A Retrospective Analysis from the VALIGA Study